Last reviewed · How we verify
Anti-OX40 antibody administration
At a glance
| Generic name | Anti-OX40 antibody administration |
|---|---|
| Also known as | MEDI6469 |
| Sponsor | Providence Health & Services |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dermatitis atopic
- NASOPHARYNGITIS
- Nasopharyngitis
- DERMATITIS ATOPIC
- Pyrexia
- COVID-19
- Influenza
- BLOOD CREATINE PHOSPHOKINASE INCREASED
- HEADACHE
- Headache
- Cough
- Aphthous ulcer
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-OX40 antibody administration CI brief — competitive landscape report
- Anti-OX40 antibody administration updates RSS · CI watch RSS
- Providence Health & Services portfolio CI